Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Novartis
|
| gptkbp:acquisitionYear |
2024
|
| gptkbp:CEO |
gptkb:Jean-Paul_Kress
|
| gptkbp:collaboratedWith |
gptkb:Incyte
gptkb:Novartis GlaxoSmithKline |
| gptkbp:country |
gptkb:Germany
|
| gptkbp:focus |
immunology
oncology therapeutic antibodies |
| gptkbp:founded |
1992
|
| gptkbp:founder |
gptkb:Andreas_Plückthun
gptkb:Simon_Moroney |
| gptkbp:headquarters_location |
gptkb:Planegg
|
| https://www.w3.org/2000/01/rdf-schema#label |
MorphoSys
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:Prime_Standard
gptkb:TecDAX |
| gptkbp:notableProduct |
gptkb:Monjuvi
gptkb:Tafasitamab |
| gptkbp:numberOfEmployees |
~500
|
| gptkbp:researchArea |
autoimmune diseases
hematological cancers |
| gptkbp:stockExchange |
gptkb:Frankfurt_Stock_Exchange
|
| gptkbp:stockSymbol |
MOR
|
| gptkbp:website |
https://www.morphosys.com/
|
| gptkbp:bfsParent |
gptkb:Polaris_Partners
|
| gptkbp:bfsLayer |
4
|